Corcept's ALS Drug Shows 87% Lower Death Risk Despite Missing Primary Endpoint

In the long struggle against amyotrophic lateral sclerosis — a disease that has offered patients little more than a measured countdown — Corcept Therapeutics has introduced a complication worth sitting with: a drug that failed by the rules of its own trial yet appears to have kept people alive in numbers that are difficult to dismiss. The DAZALS trial's Phase 2 data, released Friday, showed dazucorilant reducing death risk by 87% at 24 weeks and 84% at one year, even as the study missed its primary endpoint — a paradox that now rests in the hands of regulators, investors, and the patients who